Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production (Q30419591)

21 June 2017

title

Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production (English)

1 reference

21 June 2017

1 reference

1

Emanuele Montomoli

1 reference

21 June 2017

Baharak Khadang

2

1 reference

21 June 2017

Simona Piccirella

3

1 reference

21 June 2017

Claudia Trombetta

4

1 reference

21 June 2017

Elisa Mennitto

5

1 reference

21 June 2017

Ilaria Manini

6

1 reference

21 June 2017

Valerio Stanzani

7

1 reference

21 June 2017

Giulia Lapini

8

1 reference

21 June 2017

publication date

1 May 2012

1 reference

Expert Review of Vaccines

21 June 2017

published in

1 reference

21 June 2017

volume

11

1 reference

21 June 2017

issue

5

1 reference

21 June 2017

page(s)

587-594

1 reference

Vaccines for pandemic influenza

21 June 2017

cites work

1 reference

Of chickens and men: avian influenza in humans.

21 January 2018

1 reference

Novel swine-origin influenza A virus in humans: another pandemic knocking at the door.

21 January 2018

1 reference

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

21 January 2018

1 reference

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children

21 January 2018

1 reference

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial

21 January 2018

1 reference

The Receptor-Binding Domain of Influenza Virus Hemagglutinin Produced in Escherichia coli Folds into Its Native, Immunogenic Structure

21 January 2018

1 reference

Continuous cell lines as a production system for influenza vaccines.

21 January 2018

1 reference

Cell-based influenza vaccines: progress to date.

21 January 2018

1 reference

Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: implications for vaccine manufacture

21 January 2018

1 reference

Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial.

21 January 2018

1 reference

Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production

21 January 2018

1 reference

Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern.

21 January 2018

1 reference

Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.

21 January 2018

1 reference

Development of a novel recombinant influenza vaccine in insect cells.

21 January 2018

1 reference

The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines.

21 January 2018

1 reference

Unraveling trafficking of the kidney anion exchanger 1 in polarized MDCK epithelial cells

21 January 2018

1 reference

Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive c

21 January 2018

1 reference

Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).

21 January 2018

1 reference

Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs

21 January 2018

1 reference

A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines

21 January 2018

1 reference

Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.

21 January 2018

1 reference

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

21 January 2018

1 reference

New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses.

21 January 2018

1 reference

A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine

21 January 2018

1 reference

Appropriate glycosylation of recombinant proteins for human use: implications of choice of expression system

21 January 2018

1 reference

FluBlok, a next generation influenza vaccine manufactured in insect cells

21 January 2018

1 reference

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

21 January 2018

1 reference

Influenza vaccines based on virus-like particles

21 January 2018

1 reference

Induction of long-term protective immune responses by influenza H5N1 virus-like particles.

21 January 2018

1 reference

Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

21 January 2018

1 reference

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle

21 January 2018

1 reference

Correlates of protection: novel generations of influenza vaccines.

21 January 2018

1 reference

Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.

21 January 2018

1 reference

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

21 January 2018

1 reference

Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness

21 January 2018

1 reference

Humoral and cell-mediated immunity to vero cell-derived influenza vaccine

21 January 2018

1 reference

H5N1 vaccines: how prepared are we for a pandemic?

21 January 2018

1 reference

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

21 January 2018

1 reference

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

21 January 2018

1 reference

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

21 January 2018

1 reference

Emergence and pandemic potential of swine-origin H1N1 influenza virus

21 January 2018

1 reference

Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.

21 January 2018

1 reference

Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial

21 January 2018

1 reference

Evaluation of serological trials submitted for annual re-licensure of influenza vaccines to regulatory authorities between 1992 and 2002.

21 January 2018

1 reference

Efficacy and correlates of protection for cell culture-derived and egg-derived inactivated influenza vaccines in younger adults.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.12.24

1 reference

21 June 2017

1 reference